Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 60

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 60
---
 impact our ability to conduct our business. Any of these events could significantly harm our business, financial
condition and prospects.

25

Cash Flows

The following table summarizes
our cash flows for the periods indicated:

    Three Months Ended March 31, 
  
    (in thousands) 
    2025  
    2024 
  
    Net cash and cash equivalents (used in) provided by: 

    Operating activities 
    $(6,824) 
    $(7,476)
  
    Financing activities 
     5,274  
     (2,500)
  
    Change in cash and cash equivalents 
     (1,550) 
     (9,976)
  
    Impact on cash from foreign currency translation 
     (35) 
     130 
  
    Cash and cash equivalents, beginning of period 
     20,922  
     35,848 
  
    Cash and cash equivalents, end of period 
    $19,337  
    $26,002 

Operating Activities 

Operating activities used approximately $6.8 million of cash during the three months ended March 31, 2025, and was primarily due to our
loss of $9.7 million, partially offset by non-cash stock-based compensation of $2.1 million and changes in our net operating assets and
liabilities of $0.8 million which is mainly due to an increase in accounts payable and accrued liabilities of $0.7 million.

Operating activities used
approximately $7.5 million of cash during the three months ended March 31, 2024, resulting from our loss of $11.0 million, partially offset
by changes in our net operating assets and liabilities of $1.7 million and non-cash stock-based compensation of $1.8 million. The change
in our net operating assets and liabilities was mainly due to an increase in accounts payable and accrued liabilities of $1.4 million
and a decrease in prepaid expenses of $0.4 million.

Financing Activities

During the three months ended
March 31, 2025, the Company sold 649,860 shares of common stock in exchange for net proceeds of $5.3 million.

During the three months ended
March 31, 2024, the Company repaid $2.5 million of its debt.

Critical Accounting Policies and Estimates

Our discussion and analysis
of our financial condition and results of operations is based upon our unaud